The global anti-osteoporosis therapy and fracture healing market is poised for remarkable growth, with projections indicating a rise from USD 14,051.6 million in 2023 to USD 22,427.6 million by 2033, reflecting a robust compound annual growth rate (CAGR) of 4.8% during the forecast period.
The expansion of this market is primarily driven by the increasing prevalence of osteoporosis worldwide, along with a growing number of patients seeking effective treatment options. Key industry players are strategically enhancing therapies specifically tailored for the geriatric population, which is further bolstering market growth.
Additionally, the rising incidence of bone diseases and ongoing investments in research and development for novel drug formulations are expected to significantly contribute to market dynamics. Awareness initiatives aimed at improving the diagnosis and treatment of osteoporosis are playing a pivotal role in the market’s expansion.
The proliferation of healthcare facilities, particularly trauma centers equipped to manage osteoporosis-related fractures, is also a key factor propelling market growth.
“Osteoporosis continues to present significant healthcare challenges globally, and the market’s growth trajectory underscores the critical need for innovative treatment solutions,” said a representative from Future Market Insights (FMI). “As we advance, continued investment in research and development remains essential in addressing unmet medical needs and improving patient outcomes.”
With a focus on innovation and patient-centric approaches, the global anti-osteoporosis therapy and fracture healing market is expected to thrive, ensuring better management of osteoporosis and its associated complications.
Key Takeaways:
- North America is expected to dominate the market while growing with a CAGR of 4.5% during the forecast period.
- The market in India is projected to witness a CAGR of 4.4% during the forecast period.
- The market in China is expected to grow at a 4.6% CAGR during the forecast period.
- By drug type, bisphosphonate drugs are projected to lead the segment and is estimated to grow with a CAGR of 6%.
- By route of administration, the oral segment is expected to lead the market, growing at a CAGR of 6.2%
Enhanced Interest in Market Trends: Access In-Depth Analysis and Insights with Our Full Report!
Competitive Landscape:
The anti-osteoporosis therapy and fracture healing market is extremely competitive and consists of various key industry players. These players are heavily investing in the anti-osteoporosis therapy and fracture healing drugs market.
The key industry players are: Eli Lilly and Company, Pfizer, Inc, Amgen Inc., Merck, and Company Inc., Novartis International AG, F. Hoffmann La Roche Ltd., Teva Pharmaceuticals Industries Ltd., GlaxoSmithKline Plc., Sanofi S.A., Johnson & Johnson.
Some Recent Developments In The Market Are:
- In March 2022, Teva Pharmaceuticals declared the launch of a generic version of Revlimid in the United States.
- Enzene Biosciences Ltd.’s biosimilar drug, Denosumab, received Marketing Authorization (MA) from the Drug Controller General of India (DCGI) in August 2021 for the treatment of osteoporosis in adults.
- In 2021, the United States Food and Drug Administration (FDA) authorized the use of Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk of fracture. The drug is marketed by Amgen.
More Valuable Insights Available:
Future Market Insights offers an unbiased analysis of the global anti-osteoporosis therapy and fracture healing market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the anti-osteoporosis therapy and fracture healing market, the market is segmented on the basis of drug type, route of administration, distribution channel and region.
Key Segments Profiled in the Anti-Osteoporosis Therapy and Fracture Healing Industry Survey:
By Drug Type:
- Bisphosphonates
- Calcitonin
- Hormone Replacement Therapy
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- E-Commerce
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube